Collegium Pharmaceutical (NASDAQ:COLL) Stock Jumps 4.1% – Should You Buy?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares traded up 4.1% during trading on Wednesday. The company traded as high as $22.14 and last traded at $22.4170. Approximately 32,509 shares were traded during trading, a decline of 94% from the average daily volume of 571,868 shares. The stock had previously closed at $21.53.

Analysts Set New Price Targets

COLL has been the topic of several recent analyst reports. Needham & Company LLC reduced their target price on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Zacks Research lowered shares of Collegium Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 6th. Leerink Partners began coverage on Collegium Pharmaceutical in a research note on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price target on the stock. Truist Financial initiated coverage on Collegium Pharmaceutical in a research note on Wednesday, September 9th. They issued a “buy” rating and a $49.00 price target on the stock. Finally, Barclays reduced their price target on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 19th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Collegium Pharmaceutical currently has an average rating of “Hold” and an average target price of $48.71.

Collegium Pharmaceutical Stock Up 4.0%

The firm’s 50-day simple moving average is $24.58 and its 200 day simple moving average is $31.03. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03. The stock has a market capitalization of $729.02 million, a P/E ratio of 18.08, a PEG ratio of 0.71 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $199.88 million for the quarter, compared to analysts’ expectations of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. The business’s revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.68 EPS. As a group, research analysts expect that Collegium Pharmaceutical, Inc. will post 6.18 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Freestone Grove Partners LP bought a new position in Collegium Pharmaceutical in the 2nd quarter valued at approximately $1,611,000. Globeflex Capital L P bought a new stake in Collegium Pharmaceutical during the second quarter valued at $1,915,000. Empowered Funds LLC acquired a new stake in Collegium Pharmaceutical during the second quarter worth approximately $2,045,000. Bank of New York Mellon Corp bought a new position in Collegium Pharmaceutical during the second quarter worth $8,506,000. Finally, Bank of America Corp DE acquired a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at about $9,882,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing, acquiring and commercializing medicines for central nervous system disorders. The company’s portfolio is concentrated in pain management and includes products for chronic and acute pain, opioid-induced constipation and related conditions.

Collegium’s marketed products include Xtampza ER, an extended-release oxycodone formulation designed with the company’s DETERx abuse-deterrent technology; Nucynta and Nucynta ER, tapentadol products for acute and chronic pain; Belbuca, a buprenorphine buccal film for chronic pain; and Symproic, a treatment for opioid-induced constipation.